Hironori Aramaki
Overview
Explore the profile of Hironori Aramaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takeda S, Hirao-Suzuki M, Aramaki H, Watanabe K
Forensic Toxicol
. 2022 Dec;
41(2):287-293.
PMID: 36583834
Purpose: The effects of extended Δ-tetrahydrocannabinol (Δ-THC) exposure on estrogen receptor-positive human breast cancer MCF-7 cells have been investigated; however, the effects of Δ-THC exposure for a shorter duration remain...
2.
Takeda S, Hirao-Suzuki M, Shindo M, Aramaki H
Curr Issues Mol Biol
. 2022 Sep;
44(9):3849-3858.
PMID: 36135176
Experimental evidence accumulated by our research group and others strongly suggests that (-)-xanthatin, a xanthanolide sesquiterpene lactone, exhibits anti-proliferative effects on human breast cancer cells (in vitro) as well as...
3.
Kabata H, Aramaki H, Shimamoto N
Nanoscale
. 2022 Sep;
14(36):13315-13323.
PMID: 36065798
The affinity for regulator-operator binding on DNA sometimes depends on the length of the DNA harboring the operator, which is known as the antenna effect. One-dimensional diffusion along DNA has...
4.
Hirao-Suzuki M, Takeda S, Watanabe K, Takiguchi M, Aramaki H
Arch Biochem Biophys
. 2018 Dec;
662:219-225.
PMID: 30553767
Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated nuclear transcription factors, with three characterized subtypes: PPARα, PPARβ/δ, and PPARγ. The biological correlation between the two PPAR subtypes PPARα and...
5.
Suzuki M, Takeda S, Okazaki H, Watanabe K, Takiguchi M, Aramaki H
Nat Prod Commun
. 2018 Nov;
12(5):759-761.
PMID: 30496661
We reported that cannabidiolic acid (CBDA), a non-psychotropic constituent of fiber-type cannabis plants, down-regulates the mRNA expression of cyclooxygenase-2 (COX-2) in highly aggressive MDA-MB-231 human breast cancer cells. However, the...
6.
Okazaki H, Hirao-Suzuki M, Takeda S, Takemoto Y, Mizunoe R, Haraguchi K, et al.
J Toxicol Sci
. 2018 May;
43(5):321-327.
PMID: 29743443
Bisphenol AF (BPAF) is now recognized as one of the replacements for bisphenol A (BPA). Although considerable experimental evidence suggests that BPA is an endocrine-disrupting chemical, the toxicological profile of...
7.
Okazaki H, Takeda S, Kakizoe K, Taniguchi A, Tokuyasu M, Himeno T, et al.
Biol Pharm Bull
. 2017 Nov;
40(11):1909-1916.
PMID: 29093337
Bisphenols are endocrine disruptors that are widely found in the environment. Accumulating experimental evidence suggests an adverse interaction between bisphenols and estrogen signaling. Most studies have performed experiments that focused...
8.
Okazaki H, Takeda S, Ishii H, Takemoto Y, Fujita S, Suyama M, et al.
Biol Pharm Bull
. 2017 Aug;
40(8):1192-1198.
PMID: 28769000
Thiazolidinediones (TZDs) are known as peroxisome proliferator-activated receptor γ (PPARγ) activators, and are used in the treatment of diabetes. Although the usefulness of TZDs has been demonstrated, some of their...
9.
Okazaki H, Takeda S, Matsuo S, Matsumoto M, Furuta E, Kohro-Ikeda E, et al.
J Toxicol Sci
. 2017 Jul;
42(4):417-425.
PMID: 28717100
Phthalate esters (PAEs) are man-made compounds that are used widely in industry, and the ubiquitous exposure of humans to PAEs has been reported. Although some PAEs have been suggested to...
10.
Takeda S, Okazaki H, Kudo T, Kakizoe K, Himeno T, Matsumoto K, et al.
Anticancer Res
. 2016 Nov;
36(10):5171-5182.
PMID: 27798877
Background/aim: An in vitro cell model of long-term estrogen-deprived MCF-7 (LTED) cells has been utilized to analyze the re-growth mechanisms of breast cancers treated with blockers for estrogen receptor α...